🇺🇸 Granulocyte Macrophage Colony Stimulating Factor in United States

123 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Hypotension — 18 reports (14.63%)
  2. Off Label Use — 18 reports (14.63%)
  3. Drug Ineffective — 13 reports (10.57%)
  4. Pain — 13 reports (10.57%)
  5. Pyrexia — 13 reports (10.57%)
  6. White Blood Cell Count Decreased — 11 reports (8.94%)
  7. Hypoxia — 10 reports (8.13%)
  8. Agranulocytosis — 9 reports (7.32%)
  9. Febrile Neutropenia — 9 reports (7.32%)
  10. Hypertension — 9 reports (7.32%)

Source database →

Granulocyte Macrophage Colony Stimulating Factor in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Granulocyte Macrophage Colony Stimulating Factor approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Granulocyte Macrophage Colony Stimulating Factor in United States?

Qin Ning is the originator. The local marketing authorisation holder may differ — check the official source linked above.